COVID-19 Pediatric Vaccine Hesitancy among Racially Diverse Parents in the United States
On 29 October 2021, the U.S. FDA authorized the Pfizer-BioNTech COVID-19 (SARS-CoV-2) vaccine for emergency use in children ages 5–11 years. Racial/ethnic minorities have born the greatest burden of pediatric COVID-19 infection and hospitalization. Research indicates high prevalence of parental vacc...
Main Authors: | Celia B. Fisher, Aaliyah Gray, Isabelle Sheck |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-12-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/10/1/31 |
Similar Items
-
Determinants of COVID-19 Vaccine Uptake in Adolescents 12–17 Years Old: Examining Pediatric Vaccine Hesitancy Among Racially Diverse Parents in the United States
by: Aaliyah Gray, et al.
Published: (2022-03-01) -
COVID-19 Vaccine Hesitancy among Parents of Children under Five Years in the United States
by: Celia B. Fisher, et al.
Published: (2022-08-01) -
Factors associated with HPV vaccine acceptability and hesitancy among Black mothers with young daughters in the United States
by: Aaliyah Gray, et al.
Published: (2023-04-01) -
COVID-19 Vaccine Hesitancy among Economically Marginalized Hispanic Parents of Children under Five Years in the United States
by: Celia Fisher, et al.
Published: (2023-03-01) -
Factors associated with pediatric vaccine hesitancy of parents: a cross-sectional study in Turkey
by: Selda Yörük, et al.
Published: (2021-11-01)